Most marathon runners simply hope to finish in one piece. Archie Hunt wanted to finish fast while wearing little more than a ...

The Phase 1/2 clinical trial is an international study, with 11 participating sites worldwide, sponsored by the global biopharmaceutical company, Alexion, AstraZeneca Rare Disease. The study is ...

LMNA-related dilated cardiomyopathy (LMNA-DCM) is one of the most aggressive inherited forms of heart failure. Patients often develop dangerous heart rhythm disturbances, progressive scarring of the ...

Genetic counselling implementation in dilated cardiomyopathy: A clinical consensus statement of the Heart Failure Association of the ESC, the ESC Working Group on Myocardial and Pericardial Diseases, ...

Genome-first analyses in UK Biobank and All of Us support RBM20 as an arrhythmogenic DCM gene, with an etiologic fraction of 0.53 and significant association strength. Comparative risk modeling showed ...

Heart failure can come from many causes, but for patients with phospholamban (PLN) cardiomyopathy, the disease is driven by a specific genetic mutation. This mutation can progressively weaken the ...

The phase 1/2 UPBEAT trial is currently evaluating a single intravenous infusion of AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The Food and Drug ...

Hypertrophic cardiomyopathy, a prevalent, inherited cardiomyopathy, is characterised by left ventricular hypertrophy, hypercontractility, and impaired diastolic relaxation, with or without dynamic ...

If you have hypertrophic cardiomyopathy (HCM), and especially if you have obstructive HCM that reduces blood flow out of your heart, you and your doctor may discuss ways to lower your risk of sudden ...

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of ...